Clinical Trial Of Rhodiola Rosea L. Extract SHR-5 In The Treatment Of Mild To Moderate Depression
| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 89 |
| Gender | Both Genders |
| Age Range | 18-29, 30-44, 45-64 |
42 days supplementation of 340-680mg rhodiola SHR-5 extract was able to significantly reduce the symptoms of depression in persons with diagnosed depression, with only partial dose dependence noted.
The degree of improvement ranged from 30-35% (HAMD rating scale) to 50% reduced symptoms (higher dose on BDI).
